Clinical Neuroscience

[Splenium gliomas]

ASZALÓS Zoltán1, CSATÁRY Zoltán1

DECEMBER 01, 1960

Clinical Neuroscience - 1960;13(12)

[Symptomatically, the pathology of splenic gliomas is very difficult and the mental image, which is usually consequential, and contrast studies, which are sometimes of uncertain value, are of only some help. We distinguish primary and secondary splenic tumours on the basis of our cases. In the former, we consider a multicentric origin in the callosum-hemisphaerium angle very likely. The surgical option is very limited and the surgical mortality is very high. In the case of tumours of the corpus callosum, American neurosurgeons (Alpers (1), Voris and Adson (21), etc.) have emphasised for 25 years that surgery does not improve the patient's condition. Van Gehuchten's (23) position is correct: to refrain from surgery and to use Rtg. or radium therapy. ]


  1. Magyar Néphadsereg Egészségügyi Szolgálata



Further articles in this publication

Clinical Neuroscience

[Tests for paroxysmal myoplegia. III. Permanent lesions of the muscular system. Development of metabolic myopathy. ]


[The author reviews the literature on cases of paroxysmal paralysis in which irreversible musculoskeletal lesions have been demonstrated. He describes the relevant data of two hypokalemic and two hyperkalemic cases published with Hasznos and Solti. A significant proportion of paroxysmal paralysis cases develop persistent paresis and atrophy. The almost regular development of muscle lesions is confirmed by muscle biopsy findings. Muscle biopsy showed significant pathological changes in three of our cases where permanent paresis and atrophy were not present. Permanent muscle paralysis develops in the same muscles most affected by the seizure. The weakness of the pelvifemoral distribution and the hypervoluminal leg cramps are highly reminiscent of the muse, progr. pseudohypertrophic form of dystrophy. This is the reason why the association of these two pathologies has been frequently reported in the literature. After a critical analysis of these cases, the author concludes that there is no known case of paroxysmal paralysis and dystrophia muse, progr. in the same patient. The decisive evidence on this point is provided by the difference in the pathophysiological lesions. The muscle pathological lesion of paroxysmal paralysis is essentially vacuolar degeneration. The histopathological picture of hypokalemic and hyperkalemic cases is identical. The permanent muscular lesions of paroxysmal paralysis are the result of ion shifts and colloid chemistry changes associated with seizures. The paroxysmal osmotic changes initially result in reversible vacuolar formation. Later, irreversible degeneration of the loosened vacuolar centre of the muscle fibre is initiated. A metabolic myopathy associated with periodic recurrent potassium (and sodium ?) metabolism disturbances is therefore involved. The pathogenesis and pathomechanism of the muscle lesions just outlined are also likely to be due to a potassium-deficient diet and to myopathies induced by the administration of various glucocorticoids. ]

All articles in the issue

Related contents

Clinical Neuroscience

Wnt pathway markers in low-grade and high-grade gliomas

NAGY Ádám, TOMPA Márton, KRABÓTH Zoltán, GARZULY Ferenc , MARÁCZI Alexandra , KÁLMÁN Bernadette

Aberrant activation of the Wnt pathway contributes to differentiation and maintenance of cancer stem cells underlying gliomagenesis. The aim of our research was to determine as to what degrees some Wnt markers are expressed in gliomas of different grades, lineages and molecular subtypes. Nine grade II, 10 grade III and 72 grade IV surgically removed, formalin-fixed paraffin-embedded glioma specimens were included. Mutation status of IDH1 codon 132 was defined by immunohistochemistry and pyrosequencing in all tumors. Grade II and III astrocytic and oligodendroglial tumors were further tested for the expression of p53 and ATRX by immunohistochemistry, and codeletion of 1p19q by fluorescent in situ hybridization. Expression levels of the non-canonical Wnt5a and Fzd2, and the canonical Wnt3a and beta-catenin Wnt pathway markers were determined by immunohistochemistry, and compared between subgroups stratified according to grade, lineage and the presence or absence of IDH1 R132H/C mutations. In the normal brain – grade II-IV glioma comparisons, a gradual increase was observed for the expressions of Wnt5a, Wnt3a, Fzd2 and beta-catenin. In the astroglial and oligodendroglial lineages of grade II and III gliomas, only the Wnt5a expression was significantly higher in the astroglial subgroup. Stratification according to the IDH1 status resulted in a significant increase of the Wnt3 expression in the wild type grade II-IV gliomas. These data extend previous observations and show a correlation of Wnt pathway activity with glioma grade. Further investigations of the Wnt marker expression regulation according to glioma lineage or IDH gene mutational status are in progress by using more exact molecular approaches.

Clinical Neuroscience

A case with reversible neurotoxicity induced by metronidazole

EREN Fulya, ALDAN Ali Mehmet, DOGAN Burcu Vasfiye, GUL Gunay, SELCUK Hatem Hakan, SOYSAL Aysun

Background - Metronidazole is a synthetic antibiotic, which has been commonly used for protozoal and anaerobic infections. It rarely causes dose - and duration - unrelated reversible neurotoxicity. It can induce hyperintense T2/FLAIR MRI lesions in several areas of the brain. Although the clinical status is catastrophic, it is completely reversible after discontinuation of the medicine. Case report - 36-year-old female patient who had recent brain abscess history was under treatment of metronidazole for 40 days. She admitted to Emergency Department with newly onset myalgia, nausea, vomiting, blurred vision and cerebellar signs. She had nystagmus in all directions of gaze, ataxia and incompetence in tandem walk. Bilateral hyperintense lesions in splenium of corpus callosum, mesencephalon and dentate nuclei were detected in T2/FLAIR MRI. Although lumbar puncture analysis was normal, her lesions were thought to be related to activation of the brain abscess and metronidazole was started to be given by intravenous way instead of oral. As lesions got bigger and clinical status got worse, metronidazole was stopped. After discontinuation of metronidazole, we detected a dramatic improvement in patient’s clinical status and MRI lesions reduced. Conclusion - Although metronidazole induced neurotoxicity is a very rare complication of the treatment, clinicians should be aware of this entity because its adverse effects are completely reversible after discontinuation of the treatment.

Clinical Neuroscience

[Temozolomide chemotherapy of patients with recurrent anaplastic astrocytomas and glioblastomas]


[Introduction - Anaplastic astrocytomas and glioblastomas are the most frequent and most malignant hemispherial tumours. Unfortunately, astrocytic tumours are of infiltrative character and radical removal is not possible. Recurrent malignant gliomas are rarely suitable for reoperation. In most of the cases of recurrent gliomas chemotherapy is the last choice. Patients and method - Seventy-five consecutive patients with recurrent malignant astrocytomas and glioblastomas had been treated at our institute with per os temozolomide for five days every month. The patients received two to 16 courses of chemotherapy. The toxicity, quality of life, response to chemotherapy and survival data were analysed. Results - Out of 75 patients four were excluded following the first treatment due to myelotoxicity, and allergic reactions. Among the patients treated with temozolomide in seven cases complete response, 17 partial response, 14 progressive disease were observed. In 33 cases the disease stabilized and out of them in 27% a significant neurological improvement was detected. The time to progression was 6.8 months and the median survival time 8.75 months for patients with glioblastoma and with malignant astrocytoma or malignant mixed oligoastrocytoma 9.45 and 11.15 months, respectively. The overall survival for patients with originally lower grade glioma was 70.32 and for patients with glioblastoma multiforme 17.43 months. Conclusions - Temozolomide chemotherapy in patients with recurrent malignant astrocytoma and glioblastoma proved to be efficacious and similar good results were achieved as with a nitrosourea based combined chemotherapy. Even in those patients who received previous chemotherapy temozolomide is well tolerated and a relatively long time to progression was achieved in cases of recurrent malignant gliomas. In a few number of patients where BCNU had been previously failed with temozolomide stable disease was achieved. Temozolomide seems to be a promising drug in the chemotherapy of malignant gliomas and can be applied as a second line chemotherapy, as well.]

Clinical Neuroscience

[Cerebral tumor detection by brain scintigraphy ]

TÓTH Gábor, SZÉPLAKI Zoltán, ANTÓNY Miklós

[The authors report on brain scintigraphy of 71 patients with brain tumors. They analyze their results according to localization and histological type. They highlight that hemangiomas, meningiomas, and supra tentorial gliomas are well visualized, cerebral metastases to a lesser extent. ]

Clinical Neuroscience

[Prognosis of neuroepithelial tumours by means of cell proliferation studies]


[Cell-kinetic analysis of tumours has recently been widely used in clinical oncology for prognosis of patients treated with malignant neoplasms and for controlling the efficiency of treatment protocols. Definition of biological nature of neuroepithelial tumours was based on grading depending on the severity of cellular anaplasia. Neuroepithelial tumours can be characterized not only by the histological features but also by the DNA content and abnormalities of the cell proliferation – though the relationship between histological malignancy, proliferative activity and cellular aneuploidity was found to be rather controversial according to the literature. In this review article the clinical value of cell cycle analysis such as distribution of DNA content, DNA index; S-phase fraction; proliferation-markers [MIB 1 antibody, bromdeoxy uridin labelling index, mitotic index, definition of nucleolar organization region) are discussed on the basis of personal experience and review of the appropriate literature. Flow cytometry and examination of proliferation markers have a significant role in the definition of prognosis of patients suffering from WHO grade II and III neuroepithelial tumours. Gliomas giving rise to recidivism have a rapid cell cycle already at their first occurrence, which is characterized by raised proliferation indices, and occurrence of aneuploid cell clones. An unfavourable outcome can be prognosed in patients suffering from a WHO grade II or III glioma if the DNA index is above or below 1+0.1 if the value of the S phase fraction is above 6%, if more than 1 mitosis is found in 10 large magnification field, and if the number of cells labelled with MIB 1 antibody exceeds 3 in 1 large magnification field. The literature confirms our notion that further studies of proliferation characteristics may help in the production of a malignity score of gliomas that could support the efficiency of traditional histological grading in prognosis and control of complex therapy of these tumours.]